Found 14 matching trials
Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3
PHASE3This is a parallel arm, Phase 3, double-blind, double-dummy, active-compara...
Status
Active Not Recruiting
Location
Yale University School of Medicine - Investigational Site Number: 8400003
Blood-Brain-Barrier Disruption With Cerezyme in Patient's With Parkinson's Disease
NAThis clinical trial focus on the delivery of Cerezyme® in Parkinson's Disea...
Location
Sunnybrook Health Sciences Centre
Open-Label Extension Study Evaluating Long Term Safety in Patients With Type 1 Gaucher Disease Receiving DRX008A (ERT)
PHASE1Gaucher disease is a rare lysosomal storage disorder caused by the deficien...
Location
Shaare Zedek Medical Center
An Open-Label Extension Study of GA-GCB ERT in Patients With Type 1 Gaucher Disease
PHASE3The purpose of this study is to evaluate the long-term safety of every othe...
Location
Los Angeles Medical Center
Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease
PHASE3Gaucher disease is a rare lysosomal storage disorder caused by the deficien...
Location
Duke Children's Hospital & Health Center
Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease
PHASE4The primary purpose of this study is to evaluate the effect of VPRIV therap...
Location
Cedars Sinai Medical Center
Study to Evaluate Efficacy and Safety of Imiglucerase Treatment in Chinese Patients With Gaucher Disease Type Ⅲ
PHASE4Primary Objective
* To evaluate the efficacy on hematologic manifestations...
Location
Investigational Site Number : 107
Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease
PHASE4This is a multicenter, randomized trial to compare the safety and efficacy ...
Location
Children's National Medical Center
A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease
PHASE3Gaucher disease is a rare lysosomal storage disorder caused by the deficien...
Location
Hipolito Yrigoyen
The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher Disease
PHASE3The purpose of this study is to compare and evaluate the efficacy and safet...
Location
Multiple Locations